BR112023023269A2 - Métodos de minimização de neurotoxicidade associada à terapia com células t do receptor de antígeno quimérico (car) - Google Patents

Métodos de minimização de neurotoxicidade associada à terapia com células t do receptor de antígeno quimérico (car)

Info

Publication number
BR112023023269A2
BR112023023269A2 BR112023023269A BR112023023269A BR112023023269A2 BR 112023023269 A2 BR112023023269 A2 BR 112023023269A2 BR 112023023269 A BR112023023269 A BR 112023023269A BR 112023023269 A BR112023023269 A BR 112023023269A BR 112023023269 A2 BR112023023269 A2 BR 112023023269A2
Authority
BR
Brazil
Prior art keywords
car
methods
antigen receptor
chimeric antigen
cell therapy
Prior art date
Application number
BR112023023269A
Other languages
English (en)
Inventor
Chang Jackson Carolyn
Zudaire UBANI Enrique
C Lee Erin
Jean Xu
Jenna Goldberg
Jun Qiu
C De Braganca Kevin
Marquez de MONDELO Maria
S Akram Muhammad
Nikoletta Lendvai
Yunsi Olyslager
Original Assignee
Janssen Biotech Inc
Legend Biotech Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Legend Biotech Usa Inc filed Critical Janssen Biotech Inc
Publication of BR112023023269A2 publication Critical patent/BR112023023269A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

métodos de minimização de neurotoxicidade associada à terapia com células t do receptor de antígeno quimérico (car). a presente invenção refere-se a métodos de identificação precoce e detecção de neurotoxicidade associadas à administração de terapia de células t receptoras de antígeno quimérico (car) para reduzir a ocorrência e/ou gravidade da neurotoxicidade associada ao tratamento.
BR112023023269A 2021-05-11 2022-05-10 Métodos de minimização de neurotoxicidade associada à terapia com células t do receptor de antígeno quimérico (car) BR112023023269A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163186872P 2021-05-11 2021-05-11
PCT/IB2022/054342 WO2022238901A1 (en) 2021-05-11 2022-05-10 Methods of minimizing neurotoxicity associated with chimeric antigen receptor (car) t cell therapy

Publications (1)

Publication Number Publication Date
BR112023023269A2 true BR112023023269A2 (pt) 2024-01-30

Family

ID=81850771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023269A BR112023023269A2 (pt) 2021-05-11 2022-05-10 Métodos de minimização de neurotoxicidade associada à terapia com células t do receptor de antígeno quimérico (car)

Country Status (13)

Country Link
US (1) US20230061503A1 (pt)
EP (1) EP4337959A1 (pt)
JP (1) JP2024518549A (pt)
KR (1) KR20240026124A (pt)
CN (1) CN117616279A (pt)
AR (1) AR125827A1 (pt)
AU (1) AU2022272021A1 (pt)
BR (1) BR112023023269A2 (pt)
CA (1) CA3217687A1 (pt)
IL (1) IL308345A (pt)
MX (1) MX2023013421A (pt)
TW (1) TW202309523A (pt)
WO (1) WO2022238901A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1002023A (en) 1909-06-03 1911-08-29 Arthur T Beach Rotary pump.
US8028060B1 (en) 2007-01-05 2011-09-27 Apple Inc. Background task execution over a network based on network activity idle time
CN104239134B (zh) 2013-06-21 2018-03-09 华为技术有限公司 一种众核***的任务管理方法和装置
RU2668479C2 (ru) 2014-05-22 2018-10-01 Вабко Гмбх Способ регулирования уровня транспортного средства с пневматической подвеской
US10507219B2 (en) * 2014-10-20 2019-12-17 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP4012415A3 (en) * 2015-12-04 2022-12-07 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
KR102511914B1 (ko) 2016-08-04 2023-03-21 삼성전자주식회사 자기 기억 소자 및 이의 제조 방법
CN106869907B (zh) 2017-01-19 2019-08-06 中国科学院地质与地球物理研究所 基于电场理论的近钻头无线短传地面环境下标定方法
US11413310B2 (en) * 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
US20210198372A1 (en) * 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells

Also Published As

Publication number Publication date
CN117616279A (zh) 2024-02-27
US20230061503A1 (en) 2023-03-02
IL308345A (en) 2024-01-01
MX2023013421A (es) 2023-12-06
AR125827A1 (es) 2023-08-16
AU2022272021A1 (en) 2023-11-30
KR20240026124A (ko) 2024-02-27
WO2022238901A1 (en) 2022-11-17
TW202309523A (zh) 2023-03-01
CA3217687A1 (en) 2022-11-17
EP4337959A1 (en) 2024-03-20
JP2024518549A (ja) 2024-05-01

Similar Documents

Publication Publication Date Title
Genuneit et al. Infant atopic eczema and subsequent attention‐deficit/hyperactivity disorder–a prospective birth cohort study
Zawawi et al. The impact of COVID-19 pandemic on malaria elimination
BR102021005055A2 (pt) detecção de anticorpos para sarsr-cov
Lerena et al. Mycobacterium marinum induces a marked LC3 recruitment to its containing phagosome that depends on a functional ESX‐1 secretion system
BR112018067522A2 (pt) anticorpos específicos para receptor de poliovírus humano (pvr)
Yermakova et al. Neutralizing monoclonal antibodies against disparate epitopes on ricin toxin’s enzymatic subunit interfere with intracellular toxin transport
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
Zachariadou et al. Differences in the epidemiology between paediatric and adult invasive Streptococcus pyogenes infections
CO2021005510A2 (es) Dominio de unión
BR112018006339A2 (pt) método de avaliação da normalidade do repertório imunológico e seu uso
BR112022000581A2 (pt) Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r
BR112023023269A2 (pt) Métodos de minimização de neurotoxicidade associada à terapia com células t do receptor de antígeno quimérico (car)
Chico et al. On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections
BR112019000098A2 (pt) proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio
Achbani et al. Can the 2019 novel coronavirus cause Parkinson's disease?
BR112017004591A2 (pt) montagem para sensor de força de frenagem para uma unidade de freios, veículo ferroviário com uma montagem para sensor de força de frenagem, e método para a medição de uma força de frenagem aplicada por uma unidade de freios
BR112017000640A2 (pt) anticorpos neutralizantes do vírus influenza b e suas utilizações
Javouhey et al. Similarities and differences between staphylococcal and streptococcal toxic shock syndromes in children: results from a 30-case cohort
BR112022005659A2 (pt) Parâmetros de medição associados à administração de fármacos e dispositivos de administração de fármacos que incorpora os mesmos
Slater et al. Identification of novel host-targeted compounds that protect from anthrax lethal toxin-induced cell death
Pohanka Bacillus anthracis as a biological warfare agent: infection, diagnosis and countermeasures
MA45283A1 (fr) Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela
Narváez et al. Invasive pneumococcal disease burden in hospitalized adults in Bogota, Colombia
Tinoco et al. Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults≥ 50 years of age in Mexico
UY37082A (es) Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv